Literature DB >> 15472715

CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.

Natalia Lapteva1, An-Gang Yang, Denise E Sanders, Randall W Strube, Si-Yi Chen.   

Abstract

Breast cancer cells express the chemokine receptor CXCR4 and frequently metastasize to organs with an abundant source of the CXCR4 ligand, stromal cell-derived factor 1 (SDF-1). The chemokine receptor CXCR4 plays an active role in the metastasis of breast cancer. Here, we show that a small interfering RNA (siRNA) against CXCR4 effectively downregulates CXCR4 expression in human MDA-MB-231 breast cancer cells, leading to significant decrease in breast cancer cell invasion and adhesion. It was further found that tumor cells lacking CXCR4 expression proliferated at a much slower rate than control cells in vitro. Surprisingly, tumor cells lacking CXCR4 expression failed to grow in SCID mice in repeated experiments, providing the first direct evidence for an essential role of CXCR4 in breast cancer growth in vivo. This finding suggests an expanded role for the CXCR4 molecule in tumor cell growth in vivo, in addition to its role in breast cancer metastasis. This study implies the CXCR4 molecule as a potential target to control breast tumor growth as well as metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15472715     DOI: 10.1038/sj.cgt.7700770

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  63 in total

1.  Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide.

Authors:  Xi Wang; Ping Gao; Min Long; Fang Lin; Jun-Xia Wei; Ji-Hong Ren; Lin Yan; Ting He; Yuan Han; Hui-Zhong Zhang
Journal:  Med Oncol       Date:  2010-05-11       Impact factor: 3.064

2.  Basal and steroid hormone-regulated expression of CXCR4 in human endometrium and endometriosis.

Authors:  Abigail Ruiz; Virgilio A Salvo; Lynnette A Ruiz; Perla Báez; Miosotis García; Idhaliz Flores
Journal:  Reprod Sci       Date:  2010-08-18       Impact factor: 3.060

Review 3.  RNA interference: ready to silence cancer?

Authors:  Simone Mocellin; Rodolfo Costa; Donato Nitti
Journal:  J Mol Med (Berl)       Date:  2005-11-09       Impact factor: 4.599

Review 4.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

5.  AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells.

Authors:  Steven J Greco; Shyam A Patel; Margarette Bryan; Lillian F Pliner; Debabrata Banerjee; Pranela Rameshwar
Journal:  Am J Cancer Res       Date:  2011-06-25       Impact factor: 6.166

6.  Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.

Authors:  Surojeet Sengupta; Rachel Schiff; Benita S Katzenellenbogen
Journal:  Breast Cancer Res Treat       Date:  2008-09-19       Impact factor: 4.872

7.  CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells.

Authors:  Massod Rahimi; Theodore A Toth; Careen K Tang
Journal:  Cancer Lett       Date:  2011-03-30       Impact factor: 8.679

Review 8.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

9.  SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium.

Authors:  Rebecca Marlow; Phyllis Strickland; Ji Shin Lee; Xinyan Wu; Milana Pebenito; Mikhail Binnewies; Elizabeth K Le; Angel Moran; Hector Macias; Robert D Cardiff; Saraswati Sukumar; Lindsay Hinck
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients.

Authors:  Frank M Speetjens; Gerrit Jan Liefers; Cornelis J Korbee; Wilma E Mesker; Cornelis J H van de Velde; Ronald L van Vlierberghe; Hans Morreau; Rob A Tollenaar; Peter J K Kuppen
Journal:  Cancer Microenviron       Date:  2008-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.